---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-087129"
form_type: "8-K"
ticker: "ADIL"
cik: "0001513525"
company_name: "ADIAL PHARMACEUTICALS, INC."
filed_at: "2023-11-14T23:59:59+00:00"
generated_at: "2026-06-08T03:30:23.284826+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Adial Pharma Q3 net loss narrows to $1.4M; $4M private placement extends runway into Q4 2024

## Summary
- Net loss $1.4M in Q3 2023, down 55% from $3.1M in Q3 2022.
- R&D expenses decreased $489K (70%) YoY as AD04 trial activities wound down.
- G&A expenses decreased $708K (38%) YoY due to lower compensation and headcount.
- Cash $315K at Sep 30; $4M private placement (net $3.5M) completed post-quarter extends runway into Q4 2024.
- Planning two parallel Phase 3 trials for AD04; in confidentiality agreements with potential partners.

## SEC filing metadata
- accession: 0001213900-23-087129
- form_type: 8-K
- ticker: ADIL
- cik: 0001513525
- company_name: ADIAL PHARMACEUTICALS, INC.
- filed_at: 2023-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/0001213900-23-087129-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/ea188439-8k_adialpharma.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-087129
- JSON: https://secwatch.observer/filing/0001213900-23-087129.json
- Plain text: https://secwatch.observer/filing/0001213900-23-087129.txt

## Key facts
- Earnings Releases
  ADIAL PHARMACEUTICALS, INC. reported the third quarter of 2023 results: net income Net Loss was $1.4 million for the three months ended September 30, 2023.
  - Period: the third quarter of 2023
  - Net income: Net Loss was $1.4 million for the three months ended September 30, 2023
  - Result: reported results
  source text: Adial Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1513525/000121390023087129/0001213900-23-087129-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.